Objective
The aim of this study was to investigate the expression of CD147 and matrix metalloprpteinsae 9 (MMP-9) in children with non-Hodgkin’s lymphoma (NHL) and the relations between expressions of CD147 & MMP-9 and the clinical indexes.
Methods
Specimens excised from NHL patients were prepared. Expression of CD147 and MMP-9 were tested by SABC immunohistochemistry and its correlation to clinical results were analyzed in this report.
Results
The positive rate of CD147 expression was 73% (45/62), and that of MMP-9 expression was 81% (50/62). There was a positive correlation between CD147 and MMP-9 expressions. CD147 expression intensity was linked to clinical myelo-infiltration, tumor size, LDH value, and clinical staging (P < 0.05), rather than children age, gender, or immune typing (P > 0.05); MMP-9 expression intensity was linked to myelo-infiltration, and clinical staging (P < 0.05), rather than age, gender, immune typing, tumor size, or LDH value (P > 0.05). Five-year survival rates were 78% (22/28 ) and 45% (15/34) in CD147 (−)-(+) and (++)-(+++) cases respectively, and those were 84% (21/25) and 43% (16/37) in MMP-9 (−)-(+) and (++)-(+++) cases respectively, the difference was significant.
Conclusion
The elevated expression of CD147 and/or MMP-9 correlates with a poor clinical outcome in patients with NHL.